Lumentum (LITE) stock plunges 11% as AI-optics names slide despite Needham’s $470 target

Lumentum (LITE) stock plunges 11% as AI-optics names slide despite Needham’s $470 target

New York, Jan 8, 2026, 13:58 EST — Regular session

  • Lumentum shares drop about 11% in afternoon trade after touching near $400 earlier
  • Needham’s Ryan Koontz raised his target to $470, calling Lumentum a 2026 “top pick”
  • Traders eye Friday’s U.S. jobs report and Lumentum’s Feb. 3 results as the next tests

Lumentum Holdings Inc (LITE.O) shares slid 10.9% to $350.22 on Thursday, after topping $399.88 earlier in the session and then sinking as low as $343.41. More than 11 million shares had changed hands by early afternoon.

The move mattered because it snapped a sharp run that has turned the stock into a high-beta proxy for data-center buildouts. Lumentum jumped 11.3% on Tuesday to close at $397.42, a reminder of how fast money has been moving through the AI-linked optics trade. Investors

The selloff was not just about one name. The Nasdaq-heavy QQQ ETF was down about 0.6% while the small-cap Russell 2000 proxy, IWM, was up about 1.1%, a split that often shows up when investors rotate away from pricey growth. Friday’s U.S. employment report is due at 8:30 a.m. EST, a release that can jolt rate expectations and, by extension, the kind of stocks that have run far, fast. Bureau of Labor Statistics

Needham raised its price target on Lumentum to $470 from $290 and kept a buy rating, according to reports. “We hate to sound repetitive, but LITE will remain our top pick again in 2026,” analyst Ryan Koontz wrote in a note cited by Seeking Alpha; Needham pointed to optical circuit switching and co-packaged optics (putting optical links next to chips to cut power and latency) as potential growth drivers. Investing

Lumentum fell with the pack. Coherent dropped 8.6%, Ciena slid 14.0% and Applied Optoelectronics shed 14.0% in the same session.

Lumentum makes optical and photonic parts used in telecom and data-center networks and sells industrial lasers used in manufacturing. Those end-markets have tied the stock’s day-to-day trading more closely to cloud and AI-capex signals than it used to be. Reuters

The company said it will release fiscal second-quarter 2026 results on Feb. 3 after the market closes and hold a webcast at 5:00 p.m. ET. Investors will be listening for what management says about demand in data-center interconnect and other high-speed optical links that sit in the “plumbing” of AI clusters.

Options traders are already pricing in big swings into that report. Lumentum’s 30-day options-implied volatility — a gauge taken from option prices — was 109.15% on Jan. 6, according to Fintel. Fintel

But the setup cuts both ways. If February results or guidance fail to justify the recent re-rating tied to AI networking spend, the stock can fall quickly, especially in a tape that turns sensitive to rates and macro data.

Stock Market Today

  • Vesuvius narrative shifts after Q3 update as targets diverge
    January 9, 2026, 8:57 PM EST. Vesuvius' fair value anchor sits near £4.57, with a lower discount rate of 10.41% and a modest cut to assumed revenue growth to 3.59%, reflecting a balanced read from recent Street research. Bullish voices point to a robust Q3 trading update and company-specific drivers, while bears flag execution risk and tighter upside. The result is a valuation that's being fine-tuned rather than reset. Analysts' targets diverge: Jefferies lifts to 550p, Berenberg to 460p, and Deutsche Bank to 440p, keeping a mostly constructive stance. On the cautious side, JPMorgan nudges to 350-340p with Neutral, underscoring near-term uncertainties. With fiscal 2025 guidance implying £1.82 billion in revenue, the stock remains finely balanced as execution and growth expectations are debated by the market.
Bitcoin price today steadies near $91,000 as Strategy stock climbs on MSCI index reprieve
Previous Story

Bitcoin price today steadies near $91,000 as Strategy stock climbs on MSCI index reprieve

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger
Next Story

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Go toTop